Elucidating epigenetic landscape of gastric premalignant lesions through genome-wide mapping of 5-hydroxymethylcytosines: A 12-yearmedian follow-up study

Abstract

	•A largest longitudinal follow-up study of gastric precursor lesions in Chinese patients.
	•Revealing novel 5hmC molecular landscape linked to gastric premalignant lesions.
	•The feasibility of an innovative 5hmC-based predictive model for assessing gastric cancer progression risk.

Keywords

5-hydroxymethylcytosine / cancer prevention / gastric adenocarcinoma / gastric premalignant lesions / machine learning

References

[1] SmythEC, Nilsson M, GrabschHI, et al. Gastric cancer. Lancet North Am Ed. 2020; 396: 635-648.

[2] YanX, LeiL, LiH, et al. Stomach cancer burden in China: epidemiology and prevention. Chin J Cancer Res. 2023; 35: 81.

[3] WeedenCE, HillW, LimEL, Grönroos E, SwantonC. Impact of risk factors on early cancer evolution. Cell. 2023; 186: 1541-1563.

[4] KoulisA, BuckleA, BoussioutasA. Premalignant lesions and gastric cancer: current understanding. World J Gastrointest Oncol. 2019; 11: 665-678.

[5] LeungWK, SungJJY. Intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther. 2002; 16: 1209-1216.

[6] BlairVR, McLeodM, CarneiroF, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020; 21: e386-e397.

[7] NieminenAA, KonttoJ, PuolakkainenP, et al. Comparison of operative link for gastritis assessment, operative link on gastric intestinal metaplasia assessment, and TAIM stagings among men with atrophic gastritis. World J Gastroenterol. 2020; 26: 3447-3457.

[8] MoosaviA, Ardekani AM. Role of epigenetics in biology and human diseases. Iran Biomed J. 2016; 20: 246-258. doi:10.22045/ibj.2016.01

[9] CorreaP. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735-6740.

[10] WangF, MengW, WangB, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 2014; 345: 196-202.

[11] SpagnolLW, Polettini J, SilveiraDA, WegnerGRM, PaivaDFF. P16 gene promoter methylation is associated with oncogenesis and progression of gastric carcinomas: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022; 180: 103843.

[12] HideuraE, Suehiro Y, NishikawaJ, et al. Blood free-circulating DNA testing of methylated RUNX3 is useful for diagnosing early gastric cancer. Cancers (Basel). 2020; 12: 789.

[13] XuJ, LiN, DengW, Luo S. Discovering the mechanism and involvement of the methylation of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and its special locus region in gastric cancer. Bioengineered. 2021; 12: 1286-1298.

[14] ChangM-S, UozakiH, ChongJ-M, et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res. 2006; 12: 2995-3002.

[15] AnC, ChoiI-S, YaoJC, et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res. 2005; 11: 656-663.

[16] LiY, LiangJ, HouP. Hypermethylation in gastric cancer. Clin Chim Acta. 2015; 448: 124-132.

[17] HermanJG. Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol. 1999; 9: 359-367.

[18] RenY, ZhangZ, SheY, et al. A highly sensitive and specific non-invasive test through genome-wide 5-hydroxymethylation mapping for early detection of lung cancer. Small Methods. 2023; 8: 2300747.

[19] CuiX-L, NieJ, KuJ, et al. A human tissue map of 5-hydroxymethylcytosines exhibits tissue specificity through gene and enhancer modulation. Nat Commun. 2020; 11: 6161.

[20] CaiJ, ZengC, HuaW, et al. An integrative analysis of genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA detects noninvasive diagnostic markers for gliomas. Neurooncol Adv. 2021; 3: vdab049.

[21] TabishAM, ArifM, SongT, et al. Association of intronic DNA methylation and hydroxymethylation alterations in the epigenetic etiology of dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2019; 317: H168-H180.

[22] Rodríguez-AguileraJR, EcsediS, Goldsmith C, et al. Genome-wide 5-hydroxymethylcytosine (5hmC) emerges at early stage of in vitro differentiation of a putative hepatocyte progenitor. Sci Rep. 2020; 10: 7822.

[23] PfeiferGP, XiongW, HahnMA, Jin S-G. The role of 5-hydroxymethylcytosine in human cancer. Cell Tissue Res. 2014; 356: 631-641.

[24] LiW, ZhangX, LuX, et al. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. Cell Res. 2017; 27: 1243-1257.

[25] CaiJ, ChenL, ZhangZ, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019; 68: 2195-2205.

[26] ZengC, StroupEK, ZhangZ, et al. Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy. Cancer Commun (Lond). 2019; 39: 12.

[27] WuF, LiX, LoosoM, et al. Spurious transcription causing innate immune responses is prevented by 5-hydroxymethylcytosine. Nat Genet. 2023; 55: 100-111.

[28] CuiX-L, NieJ, KuJ, et al. A human tissue map of 5-hydroxymethylcytosines exhibits tissue specificity through gene and enhancer modulation. Nat Commun. 2020; 11: 6161.

[29] DixonMF, GentaRM, YardleyJH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996; 20: 1161-1181.

[30] Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14: 101-112.

[31] BosmanFT, Carneiro F, HrubanRH, TheiseND. WHO Classification of Tumours of the Digestive System. IARC Publications.

[32] HanD, LuX, ShihAH, et al. A highly sensitive and robust method for genome-wide 5hmC profiling of rare cell populations. Mol Cell. 2016; 63: 711-719.

[33] SongC-X, Szulwach KE, FuY, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol. 2011; 29: 68-72.

[34] LangmeadB, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012; 9: 357-359.

[35] LoveMI, HuberW, AndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15: 550.

[36] JohnsonWE, LiC, RabinovicA. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007; 8: 118-127.

[37] BenjaminiY, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995; 57: 289-300.

[38] EbrahimpoorM, GoemanJJ. Inflated false discovery rate due to volcano plots: problem and solutions. Brief Bioinform. 2021; 22: bbab053.

[39] HarrisMA, ClarkJ, IrelandA, et al. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2004; 32: D258-D261.

[40] KanehisaM, SatoY, KawashimaM, et al. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016; 44: D457-D462.

[41] HuangDW, Sherman BT, LempickiRA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37: 1-13.

[42] WuT, HuE, XuS, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2:100141.

[43] GentlemanRC, CareyVJ, BatesDM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5: R80.

[44] WangQ, QiaoW, ZhangH, et al. Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma. Front Immunol. 2022; 13: 1019638.

[45] UdaltsovaN, Silverberg MJ. SAS® macros for standard incidence ratio calculation. https://www.lexjansen.com/wuss/2014/33_Final_Paper_PDF.pdf

[46] ZhangY, SunL, LeiC, et al. A sweet warning: mucin-type O-glycans in cancer. Cells. 2022; 11: 3666.

[47] ZhangY-L, WangR-C, ChengK, et al. Roles of Rap1 signaling in tumor cell migration and invasion. Cancer Biol Med. 2017; 14: 90-99.

[48] OhshimaH, SawaT, AkaikeT. 8-Nitroguanine, a product of nitrative DNA damage caused by reactive nitrogen species: formation, occurrence, and implications in inflammation and carcinogenesis. Antioxid Redox Signal. 2006; 8: 1033-1045.

[49] PeiJ, VeluP, ZareianM, et al. Effects of syringic acid on apoptosis, inflammation, and AKT/mTOR signaling pathway in gastric cancer cells. Front Nutr. 2021; 8: 788929.

[50] AjeigbeK, Aibangbee K, SaeedS, et al. Folic acid protects and heals gastric mucosa: role of acid output, inflammatory cytokines, angiogenic and growth factors. J Basic Appl Zool. 2022; 83: 15.

[51] KoushyarS, PowellAG, VincanE, Phesse TJ. Targeting Wnt signaling for the treatment of gastric cancer. Int J Mol Sci. 2020; 21: 3927.

[52] TodiscoA. Regulation of gastric metaplasia, dysplasia, and neoplasia by bone morphogenetic protein signaling. Cell Mol Gastroenterol Hepatol. 2017; 3: 339-347.

[53] StrehlJD, HoegelJ, HornicekI, et al. Immunohistochemical expression of IMP3 and p53 in inflammatory lesions and neoplastic lesions of the gastric mucosa. Int J Clin Exp Pathol. 2014; 7: 2091-2101.

[54] GarusiE, RossiS, PerrisR. Antithetic roles of proteoglycans in cancer. Cell Mol Life Sci. 2012; 69: 553-579.

[55] CorreaP, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012; 13: 2-9.

[56] LiD, Bautista MC, JiangS-F, et al. Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: a population-based study. Am J Gastroenterol. 2016; 111: 1104-1113.

[57] VannellaL, LahnerE, OsbornJ, et al. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther. 2010; 31: 1042-1050.

[58] CaiQ, ZhuC, YuanY, et al. Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study. Gut. 2019; 68: 1576-1587.

[59] ZhangW, LiZ, AkramMS, et al. Gastric cancer screening methods: a comparative study of two scoring methods. Cancer Manag Res. 2021; 13: 5785-5791.

[60] XiaoZ, WuW, WuC, et al. 5-Hydroxymethylcytosine signature in circulating cell-free DNA as a potential diagnostic factor for early-stage colorectal cancer and precancerous adenoma. Mol Oncol. 2021; 15: 138-150.

[61] TianX, SunB, ChenC, et al. Circulating tumor DNA 5-hydroxymethylcytosine as a novel diagnostic biomarker for esophageal cancer. Cell Res. 2018; 28: 597-600.

[62] GulerGD, NingY, KuC-J, et al. Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA. Nat Commun. 2020; 11: 5270.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.